Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes

P. Pavek, L. Stejskalova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak,

. 2012 ; 3 () : 1.

Language English Country Switzerland

Document type Journal Article

The small/short heterodimer partner (SHP, NR0B2) is a nuclear receptor corepressor lacking a DNA binding domain. SHP is induced by bile acid-activated farnesoid X receptor (FXR) resulting in CYP7A1 gene suppression. In contrast, Pregnane X receptor (PXR) activation by its ligands was recently suggested to inhibit SHP gene transactivation to maximize the induction of PXR target genes. However, there are also conflicting reports in literature whether PXR or rodent Pxr activation down-regulates SHP/Shp expression. Moreover, the PXR-mediated regulation of the SHP gene has been studied only at the SHP mRNA and transactivation (gene reporter assay) levels. In this study, we studied the effect of rifampicin, a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human hepatocyte cultures. We found that SHP mRNA is not systematically down-regulated in hepatocyte in culture after 24 h treatment with rifampicin. Consistently, we did not observe down-regulation of SHP protein in primary human hepatocytes after 24 and 48 h of incubation with rifampicin. We can conclude that although we observed slight down-regulation of SHP mRNA and protein in several hepatocyte preparations, the phenomenon is unlikely critical for PXR-mediated induction of its target genes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13016213
003      
CZ-PrNML
005      
20250318105530.0
007      
ta
008      
130424s2012 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2012.00001 $2 doi
035    __
$a (PubMed)22291651
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague Hradec Kralove, Czech Republic.
245    10
$a Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes / $c P. Pavek, L. Stejskalova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak,
520    9_
$a The small/short heterodimer partner (SHP, NR0B2) is a nuclear receptor corepressor lacking a DNA binding domain. SHP is induced by bile acid-activated farnesoid X receptor (FXR) resulting in CYP7A1 gene suppression. In contrast, Pregnane X receptor (PXR) activation by its ligands was recently suggested to inhibit SHP gene transactivation to maximize the induction of PXR target genes. However, there are also conflicting reports in literature whether PXR or rodent Pxr activation down-regulates SHP/Shp expression. Moreover, the PXR-mediated regulation of the SHP gene has been studied only at the SHP mRNA and transactivation (gene reporter assay) levels. In this study, we studied the effect of rifampicin, a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human hepatocyte cultures. We found that SHP mRNA is not systematically down-regulated in hepatocyte in culture after 24 h treatment with rifampicin. Consistently, we did not observe down-regulation of SHP protein in primary human hepatocytes after 24 and 48 h of incubation with rifampicin. We can conclude that although we observed slight down-regulation of SHP mRNA and protein in several hepatocyte preparations, the phenomenon is unlikely critical for PXR-mediated induction of its target genes.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stejskalova, Lucie
700    1_
$a Krausova, Lucie
700    1_
$a Bitman, Michal $7 xx0330075
700    1_
$a Vrzal, Radim
700    1_
$a Dvorak, Zdenek
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 3 (2012), s. 1
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22291651 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130424 $b ABA008
991    __
$a 20250318105527 $b ABA008
999    __
$a ind $b bmc $g 979414 $s 814534
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 3 $d 1 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20130424

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...